Indication

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

• About Ventavis

• About the I-neb AAD
  System

• Services for Your Patients

•      PAH Pathways

• Resources

• Prescribing Information

• For Patients and
  Caregivers

Specialty Pharmacy

Once you have decided that Ventavis^® (iloprost) Inhalation Solution is right for your patient and have completed the Ventavis enrollment forms, a specialty pharmacy will be selected based upon your patient's in-network insurance status. A Ventavis-trained healthcare professional will contact your patient and discuss the following: insurance coverage and reimbursement for Ventavis and for the I-neb AAD System.

At treatment initiation, a training session will be set up with a specialty pharmacy nurse. Training can take place at your patient's home, in your office or at the local hospital. After your patient's training session, the specialty pharmacy will arrange a follow-up session to discuss any other questions or issues your patient may have regarding Ventavis or the I-neb AAD System.

Participating specialty pharmacies have a 24-hour emergency service. If your patients have a problem with their I-neb AAD System, they should contact the specialty pharmacy immediately to arrange delivery of a replacement device.
This service is available on weekends as well.

IMPORTANT SAFETY INFORMATION

Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHG. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension. Ventavis inhalation may cause brochospasm and patients with a history of hyperreactive airway disease may be more sensitive. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Ventavis has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information